Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $32.00 at Barclays

Sarepta Therapeutics (NASDAQ:SRPT - Free Report) had its price objective lifted by Barclays from $29.00 to $32.00 in a research report released on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the biotechnology company's stock.

SRPT has been the subject of a number of other reports. Oppenheimer reduced their price target on shares of Sarepta Therapeutics from $123.00 to $45.00 and set an "outperform" rating for the company in a research note on Friday, June 20th. Wolfe Research assumed coverage on shares of Sarepta Therapeutics in a research report on Tuesday, June 17th. They issued a "peer perform" rating for the company. Robert W. Baird upped their price target on shares of Sarepta Therapeutics from $30.00 to $35.00 and gave the company an "outperform" rating in a research report on Thursday. Bank of America reiterated a "neutral" rating and issued a $28.00 price objective (down previously from $76.00) on shares of Sarepta Therapeutics in a research note on Monday, June 16th. Finally, Wells Fargo & Company dropped their price objective on shares of Sarepta Therapeutics from $100.00 to $75.00 and set an "overweight" rating on the stock in a research note on Tuesday, June 17th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $57.00.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT traded up $3.59 during trading on Thursday, reaching $21.97. 19,698,423 shares of the company's stock traded hands, compared to its average volume of 2,388,922. Sarepta Therapeutics has a 12 month low of $16.88 and a 12 month high of $150.48. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. The stock has a market capitalization of $2.16 billion, a P/E ratio of -8.17 and a beta of 0.45. The company has a 50 day moving average of $28.86 and a 200-day moving average of $69.08.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. The firm had revenue of $744.86 million during the quarter, compared to the consensus estimate of $685.75 million. During the same quarter last year, the company posted $0.73 EPS. Sarepta Therapeutics's revenue for the quarter was up 80.2% on a year-over-year basis. On average, equities analysts expect that Sarepta Therapeutics will post 2.67 EPS for the current year.

Institutional Trading of Sarepta Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Janney Montgomery Scott LLC boosted its holdings in Sarepta Therapeutics by 123.5% in the 2nd quarter. Janney Montgomery Scott LLC now owns 28,743 shares of the biotechnology company's stock valued at $492,000 after purchasing an additional 15,882 shares during the period. Tempus Wealth Planning LLC increased its position in shares of Sarepta Therapeutics by 475.8% during the 2nd quarter. Tempus Wealth Planning LLC now owns 20,658 shares of the biotechnology company's stock worth $353,000 after purchasing an additional 17,070 shares in the last quarter. Public Employees Retirement System of Ohio increased its position in Sarepta Therapeutics by 2.2% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 28,792 shares of the biotechnology company's stock valued at $492,000 after acquiring an additional 607 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Sarepta Therapeutics by 21.8% in the 2nd quarter. Assenagon Asset Management S.A. now owns 867,939 shares of the biotechnology company's stock valued at $14,842,000 after acquiring an additional 155,358 shares in the last quarter. Finally, Sovran Advisors LLC increased its position in Sarepta Therapeutics by 7.2% in the 2nd quarter. Sovran Advisors LLC now owns 61,643 shares of the biotechnology company's stock valued at $1,054,000 after acquiring an additional 4,134 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.